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Antiphospholipid syndrome is characterized by arterial or venous thrombosis and the presence of antiphospholipid antibodies
(aPL). We measured β2-GPI aCL, IgGaCL, LA, antiphosphatidyl-serine antibody (PS), and antiphosphatidyl-inositol antibody
(PI) in each patient at one month after the onset of stroke. In addition, carotid artery echography was performed in patients
positive for PI or PS. Among the 250 patients, 13.6% (34/250) were positive for either PI or PS, and 6.8% (17/250) were positive
for both. Carotid artery echography performed on these 34 patients showed that the frequencies of increased intimal-medial
thickness (IMT) of 1.1 mm or more, plaque, and carotid artery stenosis of 50% or more were all signiﬁcantly higher in patients
positiveforantinuclearantibodythanthosenegativefortheantibody(P<. 05).PIandPSareassociatedwithantinuclearantibody
and precipitation of atherosclerosis. Ischemic stroke patients with SLE frequently showed a variety of antiphospholipid-protein
antibodies.
1.Introduction
In cerebrovascular disorders with an underlying immune
abnormality, antiphospholipid antibodies, of which there
are numerous types, are the leading cause of thrombosis
in the absence of acquired risk factors [1]. Cardiolipin was
the ﬁrst identiﬁed antigen for antiphospholipid antibodies,
and other anionic phospholipids were subsequently recog-
nised as antigens. It is now considered that proteins that
bind to phospholipids play an important role in throm-
bogenesis. Among these proteins, β2-glycoprotein is the
most important [2–4]. Known antigens to antiphospholipid
antibodies include cardiolipin, the anionic phospholipids
phosphatidylserine and phosphatidylinositol, and neutral
phosphatidylethanolamine. There is also a group of proteins,
including prothrombin, annexin V, protein C, protein S,
low-molecular-weight kininogen, and factor XI, that bind to
phospholipids and are known as antiphospholipid-protein
antigens [5]. Recently, the antiprothrombin antibody has
been under investigation as a possible new autoantibody.
This antibody binds to prothrombin in the presence of cardi-
olipin and phosphatidylserine [6]. To deﬁne and characterise
these antibodies, we studied their prevalence rates in patients
who had experienced cerebral infarction, and investigated
the relationships among the antibodies.
2.MaterialsandMethods
This study involved 250 patients, 155 males and 95 females
(average age 72 years), with cerebral infarction who vis-
ited our hospitals. Of these patients, one male and four
females (average age 39 years) had systemic lupus erythe-
matosus (SLE) as an underlying disease. Levels of an-
tiphospholipid antibodies, including β2-glycoprotein I-
dependent anticardiolipin antibody (β2-GPI aCL), IgG
anticardiolipin antibody (IgG aCL), lupus anticoagu-
lant (LA), antiphosphatidyl-serine antibody (PS), and
antiphosphatidyl-inositol antibody (PI), were determined in
the 250 patients. The level of antinuclear antibody was also
measuredinpatientspositiveforPIorPS.MeasurementofPI2 Clinical and Developmental Immunology
Table 1: Antiphospholipid-protein antibodies in stroke patients
with SLE.
Case Age/Gender β2-GPI aCL IgG-aCL LA PI PS
15 0 M + − + − +
24 1 F + − + −−
32 9 F + + + −−
43 1 F + + + + +
54 6 F −− − ++
and PS is an enzyme-linked immunosorbent assay (ELISA)
using a solid-phase method. More speciﬁcally, 100 μLo f
L-α-phosphatidyl-L-serine or L-α-phosphatidyl-L-inositol
and the 50-fold diluted serum to be tested are added to
microplates preprocessed with 5μg/mL of protamine sulfate
to allow them to react for 90 minutes at 37◦C. A buﬀer
(0.01MPBS and 0.05% Tween) is used to clean unreacted
substances,towhich100μlofperoxidase-labelledantihuman
IgG antibody is then added to allow them to react for 90
minutes at room temperature. A buﬀer is used to clean
unreacted labelled antibodies, to which 0.4mg/mL of o-
phenylenediamine solution with 0.012% hydrogen peroxide
added is then dispensed in 100-μL aliquots to leave them
standing for 20 minutes at room temperature. After that,
2.5M sulfuric acid was added to them to stop the reaction
for the measurement of their absorbance at 490nm. Results
were expressed as the cut-oﬀ index, which is equal to the
ratio of the absorbance of the serum to be tested to that
of a healthy person, with an absorbance of 1.0 or more
deﬁned as positive. In addition, carotid artery echography
was performed in patients positive for PI or PS. Assessment
of the presence of various antibodies was carried out in
patients in the chronic stage, at least 1 month after the onset
of cerebral infarction. This study was analyzed statistically
using t-test.
3. Results
The prevalence rates of the antibodies in the 250 patients
with cerebral infarction. They were 2.8% (7/250) for β2-GPI
aCL, 12.0% (30/250) for IgG aCL, 9.2% (23/250) for LA,
9.6%(24/250)forPS,and8.8%(22/250)forPI.Patientsaged
50 years or under accounted for 5.2% of the 250 patients
(13/250), and of these, 5 had underlying SLE (1 male and 4
females, average age 39). Of these 5 patients, 80% (4/5) were
positive for both β2-GPI aCL and LA, and 40% were positive
f o rP Io rP Sa sw e l la sβ2-GPI aCL or LA. One was negative
for β2-GPI aCL and LA and positive for PI and PS (Table 1).
Amongthe250patients,13.6%(34/250)werepositivefor
either PI or PS, and 6.8% (17/250) were positive for both. Of
the 34 patients positive for either PI or PS, 8.8% (3/34) were
positive for LA, and 8.8% (3/34) were positive for b2-GPI
aCL, with 70.6% (24/34) positive for antinuclear antibody.
Of the 24 patients positive for antinuclear antibody,
50% (12/24) had lacunar infarction, and 41.2% (10/24)
had atherothrombotic cerebral infarction. Of the patients
with lacunar infarction, 12.5% (3/24) were positive for PI
only, 16.7% (4/24) were positive for PS only, and 20.8%
Table 2: Clinical and laboratory ﬁndings in patients with PI and
PS.
Case Age Gender PI PS β2-GPIaCL ANA Type of
(y) stroke
16 8 M a l e 0 . 5 1 . 4 ( −)D 8 0 × L
26 3 M a l e 1 . 1 1 ( −)D 8 0 × C
37 2 M a l e 2 . 1 0 . 6 ( −)( −)L
45 8 M a l e 1 . 9 1 . 7 ( −)D 8 0 × A
56 4 F e m a l e 1 . 6 1 . 5 ( −)D 8 0 × L
67 8 M a l e 0 . 8 1 . 3 ( −)D 4 0 × L
7 48. Female 1.9 1.5 (−) D640× L
86 6 M a l e 1 0 . 5 ( −)( −)L
94 3 M a l e 1 . 8 0 . 7 ( −) N160× A
10 71 Male 1.1 1 (−)S P 4 0 × L
11 70 Male 1.9 0.8 (−)D 8 0 × A
12 60 Male 1.4 1.1 (−)D 4 0 × A
13 64 Male 1.1 0.9 (−)S P 4 0 × L
14 49 Male 2.1 0.9 (−)L A+ ( −)A
15 58 Male 1.5 1.4 (−) D+N40× A
16 68 Female 1.5 1.2 (−) D160× L
17 53 Female 8.1 1.1 (−)S P N 8 0 × A
18 72 Female 1.5 1 (−)S P 8 0 × L
19 71 Male 1 0.7 (−)( −)L
20 73 Female 1.3 0.8 (−)S P 8 0 × L
21 64. Female 1.1 1.3 (−) D640× A
22 81 Male 1 0.9 (−)S P 4 0 × L
23 76. Male 1.3 1.6 (−)S P 4 0 × A
24 80 Male 1 1.3 (−)D 8 0 × A
25 83 Female 0.7 1.4 (−)( −)A
26 44 Male 2.1 1.3 (−) D2560× C
27 52. Male 2.1 2.9 (−)S P 4 0 × A
28 79 Male 0.7 1.1 (−)( −)L
29 76 Female 0.8 1.1 (−)D 8 0 × L
30 65 Male 0.8 1.1 (−)S P 4 0 × L
31 63. Female 0.5 1.8 (−)S P 4 0 × C
32 31 Male 1.4 1.3 (+) LA+ D320× A
33 50 Male 0.5 1.1 (+) LA+ (−)A
34 46 Female 5.2 7.6 (−)S P 8 0 × A
L: lacunar infarction, A: atherothrombotic infarction, C: cardiogenic embo-
lism D: diﬀuse pattern, SP: speckled pattern, and N: nucleolar pattern.
(5/24) were positive for both PI and PS. Of the patients
with atherothrombotic cerebral infarction, 4.2% (1/24) were
positive for PI only, 4.2% (1/24) were positive for PS
only, and 33.3% (8/24) were positive for both PI and PS.
The incidence of cardiogenic cerebral embolism in patients
positive for antinuclear antibody was 8.3% (2/24): 1 was
positive for PS only, and 1 was positive for both PS and
PI. One patient was positive for all of PI, PS, β2-GPI
aCL, LA, and antinuclear antibody, and this patient had
atherothrombotic cerebral infarction (Table 2).
Of the 34 patients positive for PI or PS, 79.2% were
positive for antinuclear antibody, suggesting that PI and PS
may be related to the antinuclear antibody. Carotid arteryClinical and Developmental Immunology 3
Table 3: Carotid artery echography ﬁndings of PI or PS positive
patients.
PS or PI positive patients P values
IMT  1.1 mm 48% P< . 05
IMT < 1.1 mm 23%
Plaque positive 48% P<. 05
Plaque negative 21%
Carotid artery stenosis 50% 62% P<. 05
Carotid artery stenosis <50% 31%
IMT: intimal-medial thickness (n = 34)
echography performed on these 34 patients showed that the
frequencies of increased intimal-medial thickness (IMT) of
1.1 mm or more, plaque, and carotid artery stenosis of 50%
or more were all signiﬁcantly higher in patients positive for
antinuclear antibody than those negative for the antibody
(P<. 05) (Table 3).
4. Discussion
Previous reports have suggested that the presence of
antiphospholipid antibody is a risk factor for cerebral
i n f a r c t i o ni nt h o s ea g e du n d e r4 5o r5 0y e a r s[ 7]. The
Antiphospholipid Antibodies in Stroke Study (APASS) [8]
reported that in patients with antiphospholipid antibody,
the risk of cerebral infarction was 2.31 times higher than in
those negative for the antibody, and Brey et al. [9]. reported
a 1.5 times higher risk over an observation period of 20
years. In our study of 250 patients with cerebral infarction,
the prevalence rates of the antiphospholipid antibodies β2-
GPI aCL, LA, PI and PS were higher in patients aged 50
or under with underlying SLE than in those without SLE,
suggesting that the presence of antiphospholipid antibody
may be a risk factor for juvenile cerebral infarction in
SLE patients [10]. Antiphospholipid antibodies include
anticardiolipin antibody, LA, and antibodies speciﬁc to
anionic phospholipids, including PS and PI [11, 12]. As
mentionedabove,PIandPSweredetectedin9.6%and8.8%,
respectively, of the 250 patients with cerebral infarction,
and 79.2% of these patients tested positive for antinuclear
antibody. Of the 250 patients, there were 13 aged 50 or
under (average age 43), 4 of whom were positive for PI
and PS antibodies, suggesting that the presence of these
antibodies should be determined in order to assess the risk
of juvenile cerebral infarction. Tuhrim et al. [11]c o n c l u d e d
that the presence of PI is a risk factor for juvenile cerebral
infarction, and the results of our study are consistent with
that. And also Blank et al. [13] extracted PS from two
APS patients, one with habitual abortion and the other
who developed recurrent deep thrombophlebitis three times,
and administered it to pregnant mice to observe various
parameters. In this experiment, the administration of IgG PS
to mice with immature placentas and fetuses within 9 weeks
of gestation caused prolonged aPTT, thrombocytopenia,
increases in placental death of 40% to 50%, and decreases
in the mean weights of placentas and fetuses. Based on the
results, they concluded that PS could form APS features
independently on an experimental basis and suggested that
it was important to check for the presence of PS in actual
APS patients even if aCL was negative. It is believed that this
report supports our results that PS and PI may be risk factors
for juvenile cerebral infarction. Results of carotid artery
echography in patients positive for PI or PS suggested that
these two antibodies are associated with the promotion of
arteriosclerosis.
Nosigniﬁcantdiﬀerenceinthetypeofcerebralinfarction
was observed in patients positive for antinuclear antibody,
but patients positive for both PI and PS tended to have
atherothrombotic cerebral infarction.
T h u s ,w ec o n s i d e rt h a tP Sa n dP I ,a sw e l la sβ2-GPI
aCLandLA,areimportantinscreeningforantiphospholipid
antibody syndrome and should be regarded as antibodies
associated with cerebral infarction [14]. It remains contro-
versial whether the presence of antiphospholipid antibody
is associated with an increased risk of recurrent cerebral
infarction. The APASS [15] in 1990 found that the incidence
of recurrent cerebral infarction was 9.4% and that of TIA
was 6.3% over an average observation period of 1.4 years,
while Levine et al. [16] reported in 1992 that cerebral
infarction and TIA recurred at a high incidence of 35%
over an average observation period of 1.2 years. On the
other hand, Tanne et al. [17] suggested that the presence of
antiphospholipid antibody is not a risk factor for recurrent
cerebral infarction. Further work is needed to resolve the
issue, and our follow-up study of recurrent cerebral infarc-
tion in patients positive for antiphospholipid antibodies is
under way.
The present results suggest that antiphospholipid anti-
bodiesshouldberegardedasariskfactorforjuvenilecerebral
infarction and that PS and PI, in addition to β2-GPI aCL
and LA, should be included in the routine tests conducted
in patients with cerebral infarction of unknown cause.
Antiphospholipid antibody is a risk factor for cerebral
infarction, especially in SLE patients, and in the younger
population.PSandPI,inadditiontoβ2-GPIaCLandLA,are
important in screening for antiphospholipid antibody syn-
drome and appear to be associated with cerebral infarction.
And antinuclear antibody is detected at higher frequency in
patients with cerebral infarction who are positive for PS and
PI.
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